Matinas BioPharma Receives NYSE Noncompliance Notice

Core Points - Matinas BioPharma Holdings, Inc. has received a notice from NYSE American indicating it has fallen below certain continued listing standards due to not holding its annual meeting for the fiscal year ending December 31, 2024 [1] - The company plans to hold its annual meeting by December 31, 2025, to regain compliance with NYSE American listing requirements [2] - Matinas BioPharma focuses on delivering innovative therapies through its lipid nanocrystal (LNC) platform delivery technology [3]